Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 22, 2026

Inducing Myointimal Hyperplasia Versus Atherosclerosis in Mice: An Introduction of Two Valid Models
08:34

Inducing Myointimal Hyperplasia Versus Atherosclerosis in Mice: An Introduction of Two Valid Models

Published on: May 14, 2014

Animal models for studying neointima formation.

Jamie Y Jeremy1, Anita C Thomas

  • 1Department of Cardiac Surgery, Bristol Heart Institute, University of Bristol, Bristol, UK. j.y.jeremy@bris.ac.uk

Current Vascular Pharmacology
|June 3, 2009
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD14 Blockade Modulates Macrophage-Mediated Immunological Injury in a Translational Model of Reperfused ST-Segment Elevation Myocardial Infarction.

JACC. Basic to translational science·2025
Same author

CTLA-4-Ig therapy preserves cardiac function following myocardial infarction with reperfusion.

Cardiovascular research·2025
Same author

Control of endothelial cell function and arteriogenesis by MEG3:EZH2 epigenetic regulation of integrin expression.

Molecular therapy. Nucleic acids·2024
Same author

The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice.

Cardiovascular diabetology·2023
Same author

Murine studies and expressional analyses of human cardiac pericytes reveal novel trajectories of SARS-CoV-2 Spike protein-induced microvascular damage.

Signal transduction and targeted therapy·2023
Same author

The longevity-associated BPIFB4 gene supports cardiac function and vascularization in ageing cardiomyopathy.

Cardiovascular research·2023
Same journal

Chronic Treatment with Renin-Angiotensin System Inhibitors at Hospital Admission is Associated with Improved Reperfusion and Mortality Among STEMI Patients Undergoing Mechanical Reperfusion: Insight from the ISACS-STEMI COVID-19 Registry.

Current vascular pharmacology·2026
Same journal

Steps to Walk Out of, or Side Track, Cardiovascular Disease to Achieve Longevity.

Current vascular pharmacology·2026
Same journal

Mast Cells and Cardiovascular Disorders.

Current vascular pharmacology·2026
Same journal

Occupational and Environment-Related Cardiovascular Disease: A Comprehensive Review of the Literature.

Current vascular pharmacology·2026
Same journal

Metalloproteinases 2 and 9 as Biomarkers in Acute Elevation of Blood Pressure.

Current vascular pharmacology·2026
Same journal

Is the Cardiovascular Risk Increased in Patients with Isolated Systolic Hypertension and Anemia?

Current vascular pharmacology·2026
See all related articles

Neointima formation after arterial procedures causes graft failure. This review surveys animal models for testing drugs to reduce neointima and improve outcomes.

Area of Science:

  • Vascular biology and regenerative medicine
  • Pharmacology and drug discovery
  • Surgical innovation

Background:

  • Neointima (NI) formation is a primary cause of arterial bypass graft and balloon angioplasty failure, leading to re-occlusion and thrombosis.
  • This process contributes to accelerated atherosclerosis and results in a significant failure rate (up to 50%) within 1-10 years post-intervention.
  • Current treatments like statins and drug-eluting stents have limitations, and effective drugs specifically targeting NI formation are lacking.

Purpose of the Study:

  • To provide a comprehensive survey of animal models for evaluating drugs targeting neointimal hyperplasia.
  • To identify and discuss the most relevant animal models for preclinical assessment of anti-NI therapies.
  • To aid researchers in selecting appropriate models for drug development aimed at preventing graft failure.

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Induction of Accelerated Atherosclerosis in Mice: The "Wire-Injury" Model
05:35

Induction of Accelerated Atherosclerosis in Mice: The "Wire-Injury" Model

Published on: August 25, 2020

Related Experiment Videos

Last Updated: Jun 22, 2026

Inducing Myointimal Hyperplasia Versus Atherosclerosis in Mice: An Introduction of Two Valid Models
08:34

Inducing Myointimal Hyperplasia Versus Atherosclerosis in Mice: An Introduction of Two Valid Models

Published on: May 14, 2014

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Induction of Accelerated Atherosclerosis in Mice: The "Wire-Injury" Model
05:35

Induction of Accelerated Atherosclerosis in Mice: The "Wire-Injury" Model

Published on: August 25, 2020

Main Methods:

  • Literature review of established and emerging animal models for neointima formation.
  • Focus on commonly used species in cardiovascular research: rat, rabbit, mouse, pig, and dog.
  • Analysis of model suitability for assessing drug efficacy in modulating NI development.

Main Results:

  • Identification of key animal models that recapitulate human neointima formation after vascular injury.
  • Comparative overview of the strengths and limitations of each species model for drug testing.
  • Discussion of how these models can be utilized to explore the mechanisms of NI formation and test novel therapeutic interventions.

Conclusions:

  • Animal models are essential for the preclinical evaluation of drugs aimed at inhibiting neointima formation.
  • The selection of an appropriate animal model is critical for the successful development of therapies to prevent vascular graft failure.
  • Further research utilizing these models can accelerate the discovery of effective treatments for improving long-term outcomes of vascular interventions.